Validation of the pooled cohort risk score in an Asian population - a retrospective cohort study

BMC Cardiovascular Disorders

Volumn 14, Issue 1, 2014, Pages

  Chia, Yook Chin ^a,b   Lim, Hooi Min ^a   Ching, Siew Mooi ^c  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b CURTIN UNIVERSITY   (Australia)

^c UNIVERSITY PUTRA MALAYSIA   (Malaysia)

Author keywords

Asian population; Atherosclerotic cardiovascular disease; Cardiovascular events; Framingham risk score; Malaysia; Pooled cohort risk score; Primary care; Retrospective cohort; Validation

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; ORAL ANTIDIABETIC AGENT;

ADULT; AGE DISTRIBUTION; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; ASIAN; CARDIOVASCULAR DISEASE; CARDIOVASCULAR DISEASE ASSESSMENT; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS; DIABETIC PATIENT; FEMALE; FRAMINGHAM GENERAL CARDIOVASCULAR DISEASE RISK SCORE; HEART INFARCTION; HUMAN; INTERMETHOD COMPARISON; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MIDDLE AGED; POOLED COHORT RISK SCORE; POPULATION RESEARCH; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RANDOM SAMPLE; RETROSPECTIVE STUDY; SCORING SYSTEM; SEX RATIO; VALIDATION STUDY; VALIDITY; ASIAN CONTINENTAL ANCESTRY GROUP; CARDIOVASCULAR DISEASES; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; EPIDEMIOLOGY; ETHNOLOGY; HEALTH STATUS INDICATOR; MALAYSIA; MORTALITY; PRIMARY HEALTH CARE; PROGNOSIS; REPRODUCIBILITY; RISK ASSESSMENT; RISK FACTOR;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CARDIOVASCULAR DISEASES; CHI-SQUARE DISTRIBUTION; COMORBIDITY; CORONARY DISEASE; DIABETES MELLITUS; FEMALE; HEALTH STATUS INDICATORS; HUMANS; MALAYSIA; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PRIMARY HEALTH CARE; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; STROKE;

EID: 84988514102     PISSN: None     EISSN: 14712261     Source Type: Journal    
DOI: 10.1186/1471-2261-14-163     Document Type: Article

References (25)

1. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW: 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American college of cardiology/American heart association task force on practice guidelines. J Am Coll Cardiol 2013, 129(25):S1-S45.
2. Muntner P, Colantonio LD, Cushman M, Goff DC Jr, Howard G, Howard VJ, Kissela B, Levitan EB, Lloyd-Jones DM, Safford MM: Validation of the atherosclerotic cardiovascular disease pooled cohort risk equations. JAMA 2014, 311(14):1406-1415.
3. Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, Folsom AR, Greenland P, Jacobs DR Jr, Kronmal R, Liu K, Nelson JC, O'Leary D, Saad MF, Shea S, Szklo M, Tracy RP: Multi-ethnic study of atherosclerosis: objectives and design. Am J Epidemiol 2002, 156(9):871-881.
4. Pencina MJ, Navar-Boggan AM, D'Agostino RB Sr, Williams K, Neely B, Sniderman AD, Peterson ED: Application of new cholesterol guidelines to a population-based sample. NEJM 2014, 370(15):1422-1431.
5. Kavousi M, Leening MJG, Nanchen D, Greenland P, Graham IM, Steyerberg EW, Ikram MA, Stricker BH, Hofman A, Franco OH: Comparison of application of the ACC/AHA guidelines, adult treatment panel III guidelines, and europeon society of cardiology guidelines for cardiovascular disease prevention in a European cohort. JAMA 2014, 311(14):1416-1423.
6. Ioannidis JP: More than a million people taking statins? Potential implications of the new cardiovascular guidelines. JAMA 2014, 311(5):463-464.
7. Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Gibbons R, Greenland P, Lackland DT, Levy D, O'Donnell CJ, Robinson JG, Schwartz JS, Shero ST, Smith SC Jr, Sorlie P, Stone NJ, Wilson PW, Jordan HS, Nevo L, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, et al: ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American college of cardiology/American heart association task force on practice guidelines [published online November 12, 2013]. Circulation 2014, 129(25 Suppl 2):S49-S73. doi:10.1161/01.cir.0000437741.48606.98. published online November 12, 2013.
8. D'Agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB: General cardiovascular risk profile for use in primary care the Framingham Heart Study. Circulation 2008, 117(6):743-753.
9. Chobanian AV, Bakris GL, Black HR, CushmanWC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ: Seventh report of the joint national committee on prevention, detection, and treatment of high blood pressure. Hypertension 2003, 42(6):1206-1252.
10. Vergouwe Y, Steyerberg EW, Eijkemans MJ, Habbema JD: Validity of prognostic models: when is a model clinically useful? Semin Urol Oncol 2002, 20(2):96-107.
11. Lemeshow S, Hosmer DWJ: A review of goodness of fit statistics for use in the development of logistic regression models. Am J Epidemiol 1982, 115(1):92-106.
12. Pencina MJ, D' Agostina RB Sr, Steyerberg EW: Extension of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011, 30(1):11-21.
13. Chin CY, Mooi VLKCS: Antihypertensive prescribing pattern and blood pressure control among hypertensive patients over a ten year period in a primary care setting in Malaysia. Life Science Journal 2013, 10(1):2031-2035.
14. MacMohan SW, Cutler JA, Furberg CD, Payne GH: The effect of drug treatment for hypertension on morbidity and mortality from cardiovascular disease: a review of randomized controlled trials. Prog Cardiovasc Dis 1986, 29(3 Suppl 1):99-118.
15. Mancia G: Blood pressure reduction and cardiovascular outcomes: past, present, and future. Am J Cardiol 2007, 100(3a):3j-9j.
16. Yu PC, Bosnyak Z, Ceriello A: The importance of glycated haemoglobin (HbA(1c)) and postprandial glucose (PPG) control on cardiovascular outcomes in patients with type 2 diabetes. Diabetes Res Clin Pract 2010, 89(1):1-9.
17. Stein EA, Raal FJ: Targeting LDL: is lower better and is it safe? Best Pract Res Clin Endocrinol Metab 2014, 28(3):309-324.
18. Chia Y: Review of tools of cardiovascular disease risk stratification: interpretation, customisation and application in clinical practice. Singapore Med J 2011, 52(2):116-123.
19. Liu J, Hong Y, D'Agostino RB Sr, Wu Z, Wang W, Sun J,Wilson PW, KannelWB, Zhao D: Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese multi-provincial cohort study. JAMA 2004, 291(21):2591-2599.
20. Laurier D, Chau NP, Cazelles B, Segond P: Estimation of CHD risk in a French working population using a modified Framingham model. J Clin Epidemiol 1994, 47(12):1353-1364.
21. Brindle P, Jonathan E, Lampe F, Walker M, Whincup P, Fahey T, Ebrahim S: Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study. BMJ 2003, 327(7426):1267.
22. Menotti A, Lanti M, Puddu P, Kromhout D: Coronary heart disease incidence in northern and southern European populations: a reanalysis of the seven countries study for a European coronary risk chart. Heart 2000, 84(3):238-244.
23. Chin CY, Pengal S: Cardiovascular disease risk in a semirural community in Malaysia. Asia Pac J Public Health 2009, 21(4):410-420.
24. Chia YC, Lim HM, Ching SM: Does use of pooled cohort risk score overestimate the use of statin?: A retrospective cohort study in a primary care setting. BMC Fam Pract 2014, 15(1):172.
25. Johansen ME, Green LA, Sen A, Kircher S, Richardson CR: Cardiovascular risk and statin use in the United States. Ann Fam Med 2014, 12(3):215-223.